Relay Therapeutics (RLAY) | Financial Analysis & Statements
Relay Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
7.0M
Operating Income
-60.6M
-866.14%
Net Income
-54.9M
-784.14%
EPS (Diluted)
$-0.32
Balance Sheet Metrics
Total Assets
621.3M
Total Liabilities
54.3M
Shareholders Equity
567.1M
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
-41.3M
Free Cash Flow
-44.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Relay Therapeutics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15.4M | 10.0M | 25.5M | 1.4M | 3.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 261.4M | 319.1M | 330.0M | 246.4M | 172.6M |
| Selling, General & Administrative | 56.7M | 76.6M | 75.0M | 66.0M | 57.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 318.1M | 395.7M | 405.0M | 312.3M | 230.0M |
| Operating Income | -302.7M | -385.7M | -379.4M | -311.0M | -227.0M |
| Operating Margin % | -1,971.6% | -3,854.0% | -1,485.3% | -22,516.4% | -7,494.5% |
| Non-Operating Items | |||||
| Interest Income | 27.0M | 34.7M | 31.0M | 8.8M | 830.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -776.0K | 13.2M | 6.4M | 11.7M | -137.7M |
| Pre-tax Income | -276.5M | -337.7M | -342.0M | -290.5M | -363.9M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -276.5M | -337.7M | -342.0M | -290.5M | -363.9M |
| Net Margin % | -1,800.6% | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% |
| Key Metrics | |||||
| EBITDA | -299.2M | -393.4M | -380.6M | -318.5M | -85.4M |
| EPS (Basic) | - | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| EPS (Diluted) | - | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Basic Shares Outstanding | - | 142867844 | 122576527 | 112233649 | 95136719 |
| Diluted Shares Outstanding | - | 142867844 | 122576527 | 112233649 | 95136719 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Relay Therapeutics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 84.0M | 124.3M | 143.7M | 151.8M | 280.1M |
| Short-term Investments | 470.5M | 657.0M | 606.4M | 847.1M | 678.0M |
| Accounts Receivable | - | - | 0 | 306.0K | 403.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 6.0M | 10.5M | 3.3M | 3.3M | 1.8M |
| Total Current Assets | 578.3M | 809.2M | 770.1M | 1.0B | 976.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 60.6M | 79.2M | 83.5M | 85.2M | 36.6M |
| Goodwill | 0 | 2.3M | 2.3M | 2.3M | 2.3M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.3M | 2.1M | 2.7M | 2.6M | 2.6M |
| Total Non-Current Assets | 43.1M | 62.1M | 73.9M | 80.3M | 32.2M |
| Total Assets | 621.3M | 871.3M | 844.0M | 1.1B | 1.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 7.7M | 14.1M | 9.2M | 10.6M | 8.3M |
| Short-term Debt | 3.8M | 5.7M | 5.0M | 4.3M | 1.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 463.0K | 2.0M | 1.2M | 26.2M | 396.0K |
| Total Current Liabilities | 25.6M | 50.7M | 30.3M | 63.7M | 24.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 28.7M | 42.8M | 48.5M | 53.5M | 21.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | 13.2M | 32.4M | 65.3M |
| Total Non-Current Liabilities | 28.7M | 42.8M | 61.7M | 85.8M | 86.3M |
| Total Liabilities | 54.3M | 93.5M | 92.0M | 149.6M | 110.6M |
| Equity | |||||
| Common Stock | 168.0K | 168.0K | 127.0K | 121.0K | 109.0K |
| Retained Earnings | -2.0B | -1.7B | -1.4B | -1.1B | -768.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 567.1M | 777.8M | 752.0M | 950.2M | 897.8M |
| Key Metrics | |||||
| Total Debt | 32.5M | 48.5M | 53.5M | 57.7M | 22.9M |
| Working Capital | 552.7M | 758.5M | 739.8M | 955.8M | 951.9M |
Balance Sheet Composition
Relay Therapeutics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -276.5M | -337.7M | -342.0M | -290.5M | -363.9M |
| Depreciation & Amortization | 3.6M | 5.5M | 5.3M | 4.1M | 3.9M |
| Stock-Based Compensation | 62.4M | 94.1M | 86.0M | 56.1M | 48.5M |
| Working Capital Changes | -13.5M | 9.7M | 4.3M | -6.7M | 94.0M |
| Operating Cash Flow | -224.0M | -241.6M | -252.8M | -248.6M | -79.8M |
| Investing Activities | |||||
| Capital Expenditures | -410.0K | -2.0M | -4.1M | -9.1M | -3.5M |
| Acquisitions | - | - | 0 | 0 | -25.3M |
| Investment Purchases | -123.0M | -650.6M | -385.5M | -535.4M | -980.7M |
| Investment Sales | 316.2M | 611.6M | 647.3M | 355.7M | 529.9M |
| Investing Cash Flow | 192.8M | -41.1M | 257.6M | -188.7M | -479.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 265.9M | 30.3M | 284.7M | 382.2M |
| Free Cash Flow | -235.9M | -251.1M | -304.4M | -238.6M | -77.9M |
| Net Change in Cash | -31.2M | -16.8M | 35.2M | -152.6M | -177.1M |
Cash Flow Trend
Relay Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-9.81
Price to Book
4.63
Price to Sales
175.64
PEG Ratio
-9.81
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-899.00%
Return on Equity
-41.12%
Return on Assets
-25.35%
Financial Health
Current Ratio
22.61
Debt to Equity
5.72
Beta
1.58
Per Share Data
EPS (TTM)
$-1.61
Book Value per Share
$3.26
Revenue per Share
$0.09
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RLAY | 2.7B | - | 4.63 | -41.12% | 0.00% | 5.72 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






